363 related articles for article (PubMed ID: 31994023)
1. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
Sellebjerg F; Blinkenberg M; Sorensen PS
CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
[TBL] [Abstract][Full Text] [Related]
2. Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.
Graf J; Mares J; Barnett M; Aktas O; Albrecht P; Zamvil SS; Hartung HP
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33406479
[TBL] [Abstract][Full Text] [Related]
3. Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis.
Jakimovski D; Weinstock-Guttman B; Zivadinov R
Expert Rev Neurother; 2023; 23(12):1053-1061. PubMed ID: 37842819
[TBL] [Abstract][Full Text] [Related]
4. Development of anti-CD20 therapy for multiple sclerosis.
Bartok B; Silverman GJ
Exp Cell Res; 2011 May; 317(9):1312-8. PubMed ID: 21510932
[TBL] [Abstract][Full Text] [Related]
5. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.
Carlson AK; Amin M; Cohen JA
Drugs; 2024 Mar; 84(3):285-304. PubMed ID: 38480630
[TBL] [Abstract][Full Text] [Related]
6. Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis.
DiSano KD; Gilli F; Pachner AR
Front Immunol; 2021; 12():676686. PubMed ID: 34168647
[TBL] [Abstract][Full Text] [Related]
7. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
Delgado SR; Faissner S; Linker RA; Rammohan K
J Neurol; 2024 Apr; 271(4):1515-1535. PubMed ID: 37906325
[TBL] [Abstract][Full Text] [Related]
8. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
[TBL] [Abstract][Full Text] [Related]
9. Briumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review.
Azhar A; Taimuri MA; Shamat SF; Ikram A; Ali S; Ali T; Khabir Y
Ann Med Surg (Lond); 2023 Oct; 85(10):4909-4912. PubMed ID: 37811115
[TBL] [Abstract][Full Text] [Related]
10. B-cell Therapy for Multiple Sclerosis: Entering an era.
Greenfield AL; Hauser SL
Ann Neurol; 2018 Jan; 83(1):13-26. PubMed ID: 29244240
[TBL] [Abstract][Full Text] [Related]
11. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management.
Alvarez E; Longbrake EE; Rammohan KW; Stankiewicz J; Hersh CM
Mult Scler Relat Disord; 2023 Nov; 79():105009. PubMed ID: 37783194
[TBL] [Abstract][Full Text] [Related]
12. Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion.
Shirani A; Stuve O; Cross AH
Neurol Clin; 2024 Feb; 42(1):137-153. PubMed ID: 37980111
[TBL] [Abstract][Full Text] [Related]
13. Ocrelizumab: a new milestone in multiple sclerosis therapy.
Mulero P; Midaglia L; Montalban X
Ther Adv Neurol Disord; 2018; 11():1756286418773025. PubMed ID: 29774057
[TBL] [Abstract][Full Text] [Related]
14. The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.
Zhong M; van der Walt A; Campagna MP; Stankovich J; Butzkueven H; Jokubaitis V
Neurotherapeutics; 2020 Oct; 17(4):1768-1784. PubMed ID: 33058021
[TBL] [Abstract][Full Text] [Related]
15. Neutropaenia complications from Ocrelizumab and Rituximab treatment.
Pang V; Seery N; Wesselingh R; Yeh W; Zhong M; Tan T; Dwyer C; Nesbitt C; Rath L; Perera D; Bridge F; Skibina O; Bosco JJ; Jokubaitis V; Marriott M; Butkueven H; Van Der Walt A; Massey J; Sutton I; Monif M
Mult Scler Relat Disord; 2024 Jan; 81():105147. PubMed ID: 38043368
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.
Nguyen AL; Gresle M; Marshall T; Butzkueven H; Field J
Br J Pharmacol; 2017 Jul; 174(13):1895-1907. PubMed ID: 28319650
[TBL] [Abstract][Full Text] [Related]
17. Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology.
Mancinelli CR; Rossi N; Capra R
Ther Clin Risk Manag; 2021; 17():765-776. PubMed ID: 34354358
[TBL] [Abstract][Full Text] [Related]
18. Ocrelizumab and ofatumumab, but not rituximab, trigger complement induction in vitro.
Førde JL; Herfindal L; Myhr KM; Torkildsen Ø; Mollnes TE; Skrede S
Int Immunopharmacol; 2023 Nov; 124(Pt B):111021. PubMed ID: 37816262
[TBL] [Abstract][Full Text] [Related]
19. Metronomic radiological surveillance in clinically stable MS patients on anti CD20 immunotherapy is redundant.
Avasarala J
Mult Scler Relat Disord; 2024 May; 85():105541. PubMed ID: 38457884
[No Abstract] [Full Text] [Related]
20. Unleashing the power of anti-CD20 immunotherapy: Mitigating multiple sclerosis risk in Epstein-Barr virus latent infections.
Alrashoudi RH
Adv Clin Exp Med; 2023 Dec; ():. PubMed ID: 38085006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
